parkinson s disease and skeletal health
Download
Skip this Video
Download Presentation
Parkinson’s Disease and Skeletal Health

Loading in 2 Seconds...

play fullscreen
1 / 54

Parkinson s Disease and Skeletal Health - PowerPoint PPT Presentation


  • 126 Views
  • Uploaded on

Parkinson’s Disease and Skeletal Health. Minneapolis VA Medicine Research Conference January 22, 2009 Howard Fink, MD, MPH. Summary. There is accumulating evidence that PD is an important osteoporosis risk factor. Summary.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Parkinson s Disease and Skeletal Health' - kimberly


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
parkinson s disease and skeletal health

Parkinson’s Disease and Skeletal Health

Minneapolis VA Medicine Research Conference

January 22, 2009

Howard Fink, MD, MPH

summary
Summary
  • There is accumulating evidence that PD is an important osteoporosis risk factor.
summary3
Summary
  • There is accumulating evidence that PD is an important osteoporosis risk factor.
  • What is that evidence?
  • By what mechanism(s) may PD be associated with osteoporosis?
  • What should be done about this?
summary4
Summary
  • There is accumulating evidence that PD is an important osteoporosis risk factor.
  • What is that evidence?
  • By what mechanism(s) may PD be associated with osteoporosis?
  • What should be done about this?
summary5
Summary
  • There is accumulating evidence that PD is an important osteoporosis risk factor.
  • What is that evidence?
  • By what mechanism(s) may PD be associated with osteoporosis?
  • What should be done about this?
parkinson s disease7
Parkinson’s Disease
  • Clinical presentation:
    • Tremor, rigidity, bradykinesia
    • Postural instability & gait disorder
    • Dementia may occur at late stages
  • Course:
    • Usually mid- to late-life onset
      • First symptoms occur at >55 yrs in 70% of patients
      • Prevalence rises to ~3% at >80 yrs
    • Slowly progressive
osteoporosis9
Osteoporosis
  • Definition:
    • Skeletal disorder w/ reduced bone strength & increased fracture risk
osteoporosis10
Osteoporosis
  • Bone strength reflects dynamic bone remodeling
    • Bone breakdown is coupled to subsequent bone formation
    • Skeleton repairs & adapts to changes in its strain exposure
  • Bone strength is function of:
    • Bone mineral density (BMD)
    • Bone geometry
    • Bone quality (i.e. architecture, turnover, damage)
osteoporosis11
Osteoporosis
  • Epidemiology:
    • There is no existing clinical measure of bone strength
    • Defined by BMD criteria (strong predictor of fracture risk)
    • FRAX calculator of absolute fracture risk to help define treatment thresholds: http://www.shef.ac.uk/FRAX/
    • Most who might be considered for treatment based on BMD or FRAX are undiagnosed
  • Consequences:
    • ~1.5 million “osteoporotic” fractures/yr in U.S., most commonly spine, hip and wrist
association of pd with osteoporosis
Association of PD with Osteoporosis
  • Multiple case-control or retrospective studies published 1987-2002 reported PD associated with lower BMD
    • None reported consistent findings at >1 skeletal site
    • Half examined BMD measures not in wide clinical use
    • No studies examined whether factors other than age & sex could have accounted for observed findings
association of pd with osteoporosis14
Association of PD with Osteoporosis
  • In prospective data from the Study of Osteoporotic Fractures (SOF)1:
    • PD associated with ~2-fold increased hip fracture risk partially attenuated by adjustment for age & baseline BMD
  • Association between PD & fractures assumed attributable in part to increased falls risk

1Taylor BC, JAGS 2004

slide15

Association Between Parkinson’s Disease and Low Bone Density and Falls in Older Men:

The Osteoporotic Fractures in Men (MrOS) Study.

Fink HA, Kuskowski MA, Orwoll ES, Cauley JA, Ensrud KE.

J Am Geriatr Soc 53:1559–1564, 2005

mros study design
MrOS Study Design
  • Ongoing multi-site, prospective cohort study of predictors of osteoporosis and fractures in older men
  • Enrolled 5995 men aged >65, primarily from population-based sources
baseline data collection
Baseline Data Collection
  • Ascertainment of PD:
    • Subject self-report to questionnaire: “Has a doctor or other healthcare provider ever told you that you had or have Parkinson’s disease?”
      • N=52 with PD
      • N=5943 with no PD
  • Measurement of BMD
    • DXA: Areal BMD (g/cm2) of lumbar spine, total hip & hip subregions
other baseline measurements
Other Baseline Measurements
  • Age, height, weight
  • PMH/comorbidities (e.g. DM, stroke, CHF, fractures, falls)
  • Medications
  • Habits (e.g. activity, diet, smoking, alcohol)
  • Self-reported function (e.g. QOL, IADLs)
  • Physical/mental performance (e.g. leg power, walking speed, balance)
  • Cognition, vision
analyses
Analyses
  • ANCOVA to estimate cross-sectional association between PD and BMD measures
  • Results expressed as mean percentage (95%CI) BMD differences between men with and without PD
  • Multivariate model construction:
    • Considered factors associated both with PD and the specific BMD measure (p<0.10)
    • Variables also examined for clinical comprehensibility, correlation with other associated variables, and degree of missing data
    • Step-wise selection (p<0.05 for retention)
fall risk
Fall Risk
  • After adjusting for age & past falls, those w/PD had 2.3-fold increased risk of multiple future falls
slide22

The association of Parkinson’s disease with bone mineral density and fracture in older women Schneider JL, Fink HA, Ewing SK, Ensrud KE, Cummings SR, for the Study of Osteoporotic Fractures (SOF) Research GroupOsteoporos Int 2008;19:1093-97

sof study design
SOF Study Design
  • Ongoing multi-site, prospective cohort studying predictors of osteoporosis and fractures in older women
  • Enrolled 9704 women aged >65, primarily from population-based sources
  • 8105 attended study visit 4 and had known PD status
sof visit 4 data collection
SOF Visit 4 Data Collection
  • Ascertainment of PD:
    • Self-report questionnaire: “Has a doctor or other healthcare provider ever told you that you had or have Parkinson’s disease?”
      • N=73 with PD
      • N=8032 with no PD
  • Measurement of BMD
    • Areal BMD (g/cm2) of lumbar spine, total hip & hip subregions with DXA
other sof measurements
Other SOF Measurements

Measured at visit 4

  • Age, height, weight
  • PMH/comorbidities (e.g. DM, stroke, CHF, fractures, falls)
  • Medications
  • Habits (e.g. activity, diet, smoking, alcohol)
  • Self-reported health status (e.g. QOL, IADLs)
  • Cognition

Measured at visit 2

  • Neuromuscular function (e.g. leg power, walking speed, balance)
analyses26
Analyses
  • Linear regression to estimate cross-sectional association between PD and hip BMD
    • Results for mean age-adjusted BMD in men with and without PD were compared with t-tests
  • Cox proportional hazards to estimate risk of incident hip, and nonspine nonhip fractures
fall risk29
Fall Risk
  • Among community-dwelling older women, after adjusting for age & weight, those w/PD had 3.7-fold increased risk of multiple future falls
slide30

Association of Parkinson’s disease with accelerated bone loss, fractures and mortality in older men: the Osteoporotic Fractures in Men (MrOS) study Fink HA, Kuskowski MA, Taylor BC, Schousboe JT, Orwoll ES, Ensrud KE, for the Osteoporotic Fractures in Men (MrOS) Study GroupOsteoporos Int 2008;19:1277-82

mros data collection
MrOS Data Collection
  • PD status ascertained at visits 1 & 2 (mean 4.6y interval):
    • Subject self-report to questionnaire: “Has a doctor or other healthcare provider ever told you that you had or have Parkinson’s disease
  • Visits 1 & 2 measurement of BMD
    • Areal BMD (g/cm2) of lumbar spine, total hip & hip subregions with DXA
mros visit 1 2 measures
MrOS Visit 1 & 2 Measures
  • Age, height, weight (weight change from baseline calculated)
  • Comorbidities (including recent falls)
  • Medications
  • Habits (e.g. activity, diet, smoking, alcohol)
  • Self-reported function (e.g. QOL, IADLs)
  • Physical/mental performance (e.g. leg power, walking speed, balance)
  • Cognition
analyses33
Analyses
  • Definition of PD: Men reported ‘PD’ at baseline, did not report ‘no PD’ at follow-up (n=46)
  • Definition of No PD: Men reported ‘no PD’ at baseline, did not report ‘PD’ at follow-up (n=5891)
  • Change in hip BMD estimable in 19 (41.3%) men with PD and 4356 (73.9%) of men without PD.
analyses34
Analyses
  • Hip BMD change could not be determined in 27 PD men:
    • 16 (34.8%) died prior to visit 2
    • 1 terminated prior to visit 2
    • 2 refused to attend visit 2 due to health problems
    • 7 completed visit 2 questionnaire but no BMD measurement
    • 1 whose contralateral hip was measured at visit 2
analyses35
Analyses
  • Age-adjusted annualized % bone loss in men with & without PD assessed using ANCOVA.
  • Variables associated with PD status (p<0.10) examined as covariates in separate age-adjusted models
  • Multivariate modeling not performed as only a small number of PD subjects had both baseline & follow-up BMD measures
impact of patient population on results
Impact of patient population on results

Volunteer cohort

+ Prospective studies allow collection of extensive pre-fx measures

  • Results may not be representative for all men with fx
    • Participants likely healthier, community-dwelling, more well-educated, etc
postulated mechanisms for pd osteoporosis association
Postulated Mechanisms for PD-Osteoporosis Association
  • Reduced mobility or neuromuscular function
  • Vitamin D deficiency
  • Altered estrogen level
  • Low weight / weight loss
  • Parkinson’s disease medications
postulated mechanisms for pd osteoporosis association40
Postulated Mechanisms for PD-Osteoporosis Association
  • Reduced activity or neuromuscular function
    • PD→reduced activity and neuromuscular function→increased bone resorption
postulated mechanisms for pd osteoporosis association41
Postulated Mechanisms for PD-Osteoporosis Association
  • Vitamin D deficiency
    • PD and osteoporosis both epidemiologically associated with vitamin D deficiency
    • Conventional thinking:
      • PD→decreased sun exposure & dietary vit D intake→decreased calcium absorption→secondary hyperparathyroidism→increased bone resorption
    • Recently theorized:
      • Vit D deficiency→decreased activation of 1,25-OH vit D in substantia nigra→disruption of brain cell function (Newmark HL, Mov Disord 2007;22:461-8)
        • Vit D receptors and 1-alpha hydroxylase distributed in brain, including most strongly in hypothalamus & substantia nigra (Eyles DW, J Chem Neuroanat 2005;29:21-30)
        • Case report of improved PD symptoms with high dose 25-OH vit D (Derex L, Mov Disord 1997;12:612-13)
postulated mechanisms for pd osteoporosis association42
Postulated Mechanisms for PD-Osteoporosis Association
  • Altered estrogen level
    • Estrogen deficiency known to cause bone loss
    • Data suggestive that estrogen deficiency also may contribute to development of PD
      • PD more common in M>F, more common in women w/reduced endogenous estrogen exposure
      • Aromatase KO mice more vulnerable to parkinsonian neurotoxin MPTP (Morale MC, Brain Res Rev 2008;57:431-43)
      • Small trials suggest ERT may improve motor symptoms in PD (Nicolleti A, Clin Neuropharm 2007;30:276-80. Tsang KL, Neurology 2000;54:2292-8)
postulated mechanisms for pd osteoporosis association43
Postulated Mechanisms for PD-Osteoporosis Association
  • Low weight / weight loss
    • Weight loss strongly associated with bone loss in prospective studies
    • Parkinson’s disease associated with weight loss, both before and after diagnosis
    • In older men, adjustment for concurrent weight loss attenuated association between PD and bone loss more than any other variable, but did not eliminate the association1

1 Fink HA, Osteoporos Int 2008;19:1277-82

postulated mechanisms for pd osteoporosis association44
Postulated Mechanisms for PD-Osteoporosis Association
  • Parkinson’s disease medications
    • From case-control data1
      • Inconsistent association between different classes of PD medications (levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors, anticholinergics) and fracture risk
      • No evidence that association varied by dose or duration of use
    • Interpretation complicated by confounding by indication

1Vestergaard P, Calcif Tissue Int 2007;81:153-61.

what to do clinical
What to Do: Clinical?
  • Treat PD patients to reduce bone loss, prevent fractures?
    • There is some evidence that osteoporosis-specific treatments reduce bone loss and prevent hip fractures in PD patients.
slide47

Amelioration of osteoporosis by menatetrenone in elderly female Parkinson’s Disease patients with vitamin D deficiency.Sato Y, et al. Bone 2002;31:114.

  • Double-blind RCT
  • 120 postmenopausal Japanese PD patients (mean 72y)
    • Exclusions: nonvertebral fx, recent or regular use of bone active meds, known cause of osteoporosis
    • Mean baseline BMD 2.2 mm Al in both groups (mean T-scores <-2.5)
  • 45 mg daily menatrenone (vitamin K2) vs. no treatment x 12m
  • Bone loss:
    • Change in 2nd metacarpal BMD (mm Al, CXD)
      • +0.9% menatrenone grp v. -4.3% no treatment grp (p<.0001)
  • Fractures:
    • 1 (1 hip) menatrenone grp vs. 10 (8 hip) no treatment grp (p=.0082)
slide48

Amelioration of osteopenia and hypovitaminosis D by 1-alpha-hydroxyvitamin D3 in elderly patients with Parkinson’s disease. Sato Y, et al. J Neurol Neurosurg Psychiatry 1999;66:64.

  • Placebo-controlled, double-blind RCT
  • 86 Japanese PD patients (mean 71y; 51 women)
    • Exclusions: nonvertebral fx, recent or regular use of bone active meds, known cause of osteoporosis
    • Mean baseline BMD 2.0-2.1 mm Al in both groups (mean T-score <-2.5 vs. normal Japanese ref range)
  • 1 mcg vit D vs. placebo daily x 18m
  • Bone loss:
    • Change in 2nd metacarpal BMD (mm Al, computed radiographic densitometry, i.e. CXD)
      • -1.2% vit D grp v. -6.7% placebo grp (p<.0001)
  • Fractures:
    • 1 (1 hip) vit D grp vs. 8 (6 hip) placebo grp (p=.0028)
slide49

Alendronate and vitamin D2 for prevention of hip fracture in Parkinson’s Disease: a randomized controlled trial. Sato Y, et al. Movement Disorders 2006;21:924.

  • Placebo-controlled, double-blind RCT
  • 288 Japanese female PD patients aged >65y (mean 72y)
    • Exclusions: nonvertebral fx, recent or regular use of bone active meds, known cause of osteoporosis
    • Mean baseline BMD 2.1-2.2 mm Al in both groups (mean T-score <-2.5)
    • 5 mg alendronate + 1000 IU ergocalciferol vs. placebo + 1000 IU ergocalciferol daily x 24m
  • Bone loss:
    • Change in 2nd metacarpal BMD (mm Al, CXD)
      • +3.1% alendronate grp vs. -2.8% placebo grp (p<.001)
  • Hip fractures:
    • 4 alendronate grp vs. 14 placebo grp (RR 0.29, 95%CI=0.10-0.85)
slide50
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson’s Disease. Sato Y, et al. Neurology 2007;68:911.
  • Placebo-controlled, double-blind RCT
  • 242 Japanese male PD patients aged >65y (mean 72y)
    • Exclusions: nonvertebral fx, recent or regular use of bone active meds, known cause of osteoporosis
    • Mean baseline BMD 2.25 mm Al in both groups (mean T-score <-2.5)
    • 2.5 mg risedronate + 1000 IU ergocalciferol vs. placebo + 1000 IU ergocalciferol daily x 24m
  • Bone loss:
    • Change in 2nd metacarpal BMD (mm Al, CXD)
      • +2.2% risedronate grp v. -2.9% placebo grp (p<.001)
  • Hip fractures:
    • 3 risedronate grp vs. 9 placebo grp (RR 0.33, 95%CI=0.09-1.20)
what to do clinical51
What to Do: Clinical?
  • Treat PD patients to reduce bone loss, prevent fractures?
    • Trials suggest that supplemental vit D and vit K2 each reduce bone loss, and that alendronate and risedronate each prevent hip fracture
    • All published trials from single investigator in Japanese osteoporotic patients with PD; generalizability to other osteoporotic PD populations unknown
    • There is no evidence yet that osteoporosis-specific treatments reduce bone loss and prevent hip fractures in PD patients without osteoporosis.
what to do clinical52
What to Do: Clinical?
  • Screen PD patients for osteoporosis?
    • Though at increased risk for osteoporosis, accelerated bone loss, falls, and fractures, patients with PD are infrequently screened for osteoporosis1
    • There is no direct evidence on the cost-effectiveness of screening this population for osteoporosis, but demonstrating this will be difficult
    • Recommendation: In addition to implementing fall prevention measures, clinicians should consider osteoporosis screening in older patients with PD

1Eng ML, Mov Disord 2006;21:2265-66

what to do research
What to Do: Research?
  • Examine PD-bone loss association in larger PD populations, including evaluation of RF for bone loss in PD patients
  • RCT to examine whether PD-specific treatment reduces BMD loss, falls & fractures
  • RCT to examine whether osteoporosis-specific treatment reduces BMD loss & fractures in nonosteoporotic PD patients
  • RCT to examine whether vitamin D and/or estrogen improve PD symptoms
  • Consider inclusion of PD as RF in absolute fracture risk models to be utilized for BMD screening, fracture prevention decisions
slide54

Contact Information

  • For information about this specific presentation please contact Howard Fink, MD, MPH at [email protected]
  • For any questions about the monthly GRECC Audio Conference Series please contact Tim Foley at [email protected] or call (734) 222-4328
  • For the link to the evaluation form for this conference that will confer CE credit please go to http://vaww.sites.lrn.va.gov/vacatalog/cu_detail.asp?id=24985and click the “Handout: Registration and Evaluation” link
ad